Integrated Biopharma, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2020
February 12, 2021 at 03:06 pm
Share
Integrated BioPharma, Inc. announced earnings results for the second quarter ended December 31, 2020. For the second quarter, the company announced sales was USD 14.257 million compared to USD 14.197 million a year ago. Operating income was USD 1.244 million compared to USD 1.205 million a year ago. Net income was USD 1.224 million compared to USD 959,000 a year ago. Basic earnings per share from continuing operations was USD 0.04 compared to USD 0.03 a year ago. For the half year, sales was USD 29.429 million compared to USD 25.603 million a year ago. Operating income was USD 2.753 million compared to USD 1.681 million a year ago. Net income was USD 2.265 million compared to USD 1.271 million a year ago. Basic earnings per share from continuing operations was USD 0.08 compared to USD 0.04 a year ago. Diluted earnings per share from continuing operations was USD 0.07 compared to USD 0.04 a year ago.
Integrated Biopharma Inc. is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements, and herbal products. The Companyâs business segments include Contract Manufacturing operated by Manhattan Drug Company, Inc. (MDC), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; and Other Nutraceutical Businesses, which includes the operations of AgroLabs, Inc. (AgroLabs), The Vitamin Factory (the Vitamin Factory), IHT Health Products, Inc. (IHT), MDC Warehousing and Distribution, Inc., and Chem International, Inc. AgroLabs distributes healthful nutritional products for sale through mass market, grocery and drug and vitamin retailers under the brands: Peaceful Sleep, and Wheatgrass and other products. IHT is a distributor of fine natural botanicals, including multi-minerals produced under a license agreement. Chem is a distributor of raw materials.
INTEGRATED BIOPHARMA, INC. 
